BOEHRINGER-INGELHEIM
12.8.2019 15:02:04 CEST | Business Wire | Press release
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for various types of cancers, including gastrointestinal and lung cancers. The establishment of a joint Virtual Research and Development Center will enable effective data sharing and analysis between the organizations.
The partnership is built on a flexible framework, allowing for projects to enter at different stages (research, development and/or clinical stage) over several years. It further combines the unique patient-driven drug-development capabilities of MD Anderson’s Therapeutics Discovery division with the innovative pipeline of novel medicines from Boehringer Ingelheim.
MD Anderson’s Therapeutics Discovery division is a multidisciplinary team of clinicians and researchers focused on advancing the next generation of cancer therapies. As part of the division, the TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology) platform conducts cutting-edge translational research to better understand how new medicines work and which patients will see most benefit.
"We could not have chosen a better partner with all its research, translational and clinical expertise in lung and gastrointestinal cancers. Together, we hope to transform the treatment landscape for these diseases by tackling their root causes and drivers, that have so far remained elusive, exploring new and smart ways of killing cancer cells," said Dr Victoria Zazulina, Corporate Vice President and Global Head of Oncology, Medicine, at Boehringer Ingelheim. "Our innovative oncology pipeline coupled with strong partnerships like this will contribute to unravelling the complexities of these diseases and bringing innovative solutions to people with various types of cancers."
The Virtual Research and Development Center will focus on the development of potential new treatments including:
- KRAS inhibition concepts, as mutations in the KRAS gene are common in various cancers, specifically in certain types of lung and gastrointestinal cancers.
- a TRAILR2 agonistic antibody, with the potential to selectively induce cancer cell death (apoptosis).
“Within MD Anderson, we are committed to a singular goal of ending cancer,” said Tim Heffernan, Ph.D., executive director of TRACTION at MD Anderson. “We look forward to working with Boehringer Ingelheim to advance their innovative pipeline of cancer medicines. Our Therapeutics Discovery team is well-poised to conduct impactful translational research, and this partnership will allow us to more rapidly advance much-needed new therapies to patients.”
More than 4.1 million people die from gastrointestinal and lung cancers every year worldwide1 , indicating an urgent need for new treatment approaches. Gastrointestinal cancers represent a heterogeneous complex array of diseases, and include oesophageal (throat), gastric (stomach), liver, pancreatic, and colorectal cancers. In 2018, lung cancer caused more than 1.7 million deaths1 . There are two main types of lung cancer: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
Please click on the link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-and-md-anderson-form-collaboration
For more information, visit:
https://www.boehringer-ingelheim.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190812005307/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Does Muscle Composition Identify High-Risk Individuals in Chronic Kidney Disease? New AMRA Medical Study Says Yes, Reveals Strong Link to Mortality23.4.2026 17:10:00 CEST | Press release
AMRA Medical researchers recently set out to answer the question: what is the relationship between adverse muscle composition (AMC) and mortality in kidney disease? Recent findings demonstrate that AMC, characterized by low muscle volume z-score and high muscle fat infiltration, is an independent and strong predictor of all-cause mortality in individuals with chronic kidney disease (CKD). The findings, published in Clinical Journal of the American Society of Nephrology, were based on data from the UK Biobank imaging study and further reinforce the clinical relevance of MRI-derived muscle biomarkers in identifying high-risk populations across chronic diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423198497/en/ AMRA's MRI-based muscle biomarkers in clinical trials Researchers from AMRA, alongside our collaborators at Linköping University (LiU), analyzed 894 participants with CKD using AMRA’s MRI-based body composi
Diligent Unveils AI Board Member and Agentic GRC Workforce at Elevate 202623.4.2026 15:00:00 CEST | Press release
Diligent’s agentic AI strengthens board oversight and transforms how GRC teams work — reducing manual effort and outside-advisor dependency, tightening control over sensitive workflows and enabling leaders to make faster, more defensible decisions Diligent, the AI leader in governance, risk and compliance (GRC) SaaS solutions, today unveiled a new generation of autonomous AI agents, including AI Board Member — a secure AI assistant for directors — and a coordinated network of agents embedded across the Diligent One Platform. Accessible through a single command center, agents automate multi-step workflows across governance, risk, compliance and third-party management, giving organizations the impact of a “GRC manager” without adding headcount. “AI supercharges teams that embrace it, and boards are no exception,” said Brian Stafford, President and CEO of Diligent. “With AI Board Member and a network of autonomous agents woven through the Diligent One Platform, we’re giving the C-suite an
Safe Software Bolsters Leadership Team with CFO and CPO Appointments to Drive Next Phase of Growth23.4.2026 15:00:00 CEST | Press release
CFO and CPO executive hires to enhance operational and financial performance on the company’s path to $250M by 2028 Safe Software (Safe), creator of FME, the only All-Data, Any-AI enterprise integration platform, today welcomes two executives to its leadership team as it moves into the next phase of growth. Judd Lee has been appointed as the company’s Chief Financial Officer (CFO), and Vanessa Ribreau has been appointed as Chief People Officer (CPO). Having recently crossed $100M in revenue, the expanded leadership team will further enable the company to scale as it accelerates toward its goal of reaching $250M in revenue by 2028. Judd Lee is a seasoned CFO with over 15 years of experience partnering closely with CEOs to align financial strategy and accelerate sustainable growth. He is known for his strong commitment to mentorship and for building high-performing global teams rooted in trust, morale and a shared sense of purpose. With more than two decades of financial leadership acros
Corpay Cross-Border Named the Official FX Supplier of Toulouse Football Club23.4.2026 14:30:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Toulouse Football Club to become their Official Foreign Exchange (FX) Supplier. A partnership brought together by SPORTFIVE, an international sports marketing agency. Through this partnership, Corpay Cross-Border will deliver comprehensive FX risk management solutions to support Toulouse Football Club’s operations. In addition, its award-winning platform will enable the club to manage global payments seamlessly through a single point of access. “Corpay Cross-Border is proud to be named the Official FX Supplier of Toulouse Football Club,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “This partnership reinforces Corpay’s position as a leading provider of corporate payments and currency risk management solutions within prof
Philip Morris International Expands its Partnership with Ducati Corse as Decades-Long Partnership Races Forward with Purpose23.4.2026 14:00:00 CEST | Press release
ZYN branding to be present at select MotoGP races in the 2026 season and beyond Philip Morris International1 (NYSE: PM) today announced an expanded partnership with Ducati Corse for the 2026 season and beyond. This next chapter introduces a major development: the ZYN brand of nicotine pouches—the number one nicotine pouch brand globally2—will feature on Ducati Corse MotoGP liveries at select races throughout the seasons. Just as Ducati pushes the limits of performance, ZYN represents PMI’s commitment to delivering innovation, offering a product that delivers exceptional quality while being thoughtfully designed. This partnership allows ZYN to connect with adult consumers in a space they’re passionate about—and to do so in a way that’s authentic, respectful, and dynamic. Philip Morris International’s relationship with Ducati Corse began in 2003—the year Ducati arrived in MotoGP—ushering in a bold new era of ambition. Since then, the collaboration has evolved alongside both organizations
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom